J AllergyClin Immunol 2009;124:1188-94 1.14 Conclusion: The Arg16 genotype of ADRB2 is associated with exacerbations in asthmatic children and young adults exposed daily to b2-agonists
Biomarker for asthma
Exhaled nitric oxide level : absolute level or personal best ?
FeNO and cost effectiveness
IgE level and asthma
IgE level correlate with asthmatic
symptom only in atopic asthma
J Allergy Clin Immunol 2009;124:447-53
Biomarker of chronic persistant asthma
Bronchial provocation test
- mannitol bronchoprovocation test
- sensitivity and specificity
Conclusion : Targeting FENO on reference values is not justified.
Conclusion : Conventional asthma management resulted in good control of symptoms in most participants. The addition of fraction of exhaled NO as an indicator of control of asthma resulted in higher doses of inhaled corticosteroids, without clinically important improvements in symptomatic asthma control.
J Allergy Clin Immunol 2009;124:928-32 . 1.25 Area = 0.89 Conclusions : In an unselected sample of young adults, bronchial provocation with inhaled dry-powder mannitol had a high diagnostic specificity for the diagnosis of asthma .
Pollution ,viral infection and social stress are studied in 2009
- positive correlation of FEV1 and
distance from roadways
- ozone increase risk of asthma
Difference of viral infection in asthma and non asthma
Conclusions: These findings suggest that subjects with mild allergic asthma and healthy subjects have similar cold symptoms and inflammatory and antiviral responses.
- increase risk of suicide or not
- effect on behavior
- increase dose of ICSs or add LABA
- high dose or low dose ICSs/LABA
- early or delay ICSs
J Allergy Clin Immunol 2009;124:699-706 . 1.34
J Allergy ClinImmunol 2009;124:691-6 . 1.35
J Allergy ClinImmunol 2009;123:116-21 1.41
Conclusion: Although symptomatic control and rescue bronchodilator use may be improved by the addition of a LABA to ICS, there may be a lower risk of severe exacerbations and hospitalizations from ICS dose increase. Oral steroid use : lower in ICS group ( 22%vs 27%) Hospitalization : lower in ICS group ( 1.3% vs 1.7%) J Allergy ClinImmunol 2009;123:116-21
ns ns ns Conclusion : low dose fixed combination and reliever therapy is associated with higher eosinophil counts, but these remain within the range associated with stable clinical control.
J Allergy Clin Immunol 2009;124:1180-5. 1.43
Conclusions: relative mild asthmatic patients with delay ICS Rx had elevate inflammatory markers but no clinical difference compare with early ICS Rx